Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT04501341

BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients

Effectivity and Safety of Autologous BM-MNC Stem Cell Therapy and Allogenic Umbilical Cord Mesenchymal Stem Cell for Type 2 Diabetes Mellitus Patients

Sponsor: Dr Cipto Mangunkusumo General Hospital

Conditions T2D

Interventions Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC Intravenous Infusion of UC-MSC

Updated 5 times since 2020 Last updated: Aug 2, 2020 Started: Mar 14, 2016 Primary completion: Dec 1, 2021 Completion: Dec 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates T2D and is currently ongoing. Dr Cipto Mangunkusumo General Hospital leads this study, which shows 5 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Nov 2022 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Nov 2022 [monthly]

Recruiting PHASE1_PHASE2
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dr Cipto Mangunkusumo General Hospital
Indonesia University

Data source: Indonesia University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jakarta Pusat, Indonesia